In line with this study, a another report have demonstrated the positive effect in vivo of a novel selective small-molecule RIPK1 inhibitor, developed by the GSK company, in a similar mouse model of PDA as well as in organoid human models (59). Here, RIPK1 is linked to Patent ductus arteriosus.